At a glance
Advancing innovation in accelerated cancer diagnosis is a national competitive grant from UK Research and Innovation for the research & development sector. Funding is up to £25.4M. Eligible applicants: See the official UKRI opportunity page; eligibility varies by council and call - most require UK-based researchers or organisations. The application deadline is October 28, 2026. Apply via the official listing at www.ukri.org.
- Amount
- Up to £25.4M
- Deadline
- 28 Oct 2026
- Type
- Competitive
- Status
- Forecasted
About this program
Funding opportunity Funding opportunity: Advancing innovation in accelerated cancer diagnosis Opportunity status: Upcoming Funders: Innovate UK Co-funders: Office for Life Sciences’ (OLS) Funding type: Grant Total fund: £25,400,000 Publication date: 20 August 2026 Opening date: 1 September 2026 9:30am UK time Closing date: 28 October 2026 11:00am UK time See the full opportunity details on the Innovation Funding Service . Innovate UK, on behalf of the OLS Cancer Healthcare Goals programme, will invest up to £25.4 million, to support the clinical validation and evaluation of early cancer diagnostic technologies and devices. Eligibility summary This competition is open to collaborations only. To lead a collaborative project your organisation must be: a UK registered business an academic institution an NHS organisation The consortium must contain at least one UK registered micro, small or...
Who can apply
See the official UKRI opportunity page; eligibility varies by council and call - most require UK-based researchers or organisations.
How to apply
Apply through the UKRI Funding Service as directed on the official opportunity page linked below.
Apply at official sourceRelated grants
- PATT travel claim for competitively awarded observation time UKRI · See listing · Rolling Open
- Research Infrastructure Renewal UKRI · £300K–£1M · 21 Oct 2026 Open
- UK-Singapore CRD 2026 UKRI · Up to £3M · 16 Dec 2026 Open
- Next generation artificial intelligence (AI): explainable AI UKRI · £603K–£10M · 20 Oct 2026 Open